PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may predict prognosis of ovarian cancer.

Abstract Platinum resistance is a critical barrier for clinicians to improve the survival of ovarian cancer. Our study evaluated the correlation between copy number variations (CNVs) of neurotrophic tyrosine receptor kinase 3 (NTRK3) and the prognosis of ovarian cancer, which might predict platinum resistance in ovarian cancer patients.Array comparative genomic hybridization (CGH) was used to test gene backgrounds between platinum-sensitive and platinum-resistant relapsed populations and CNVs of NTRK3 were indicated by cluster analysis. Fluorescence in situ hybridization (FISH) was adopted in 41 cases for further verification, which confirmed the results of array CGH. Spearman's rank correlation analysis and χ test were used to evaluate the accuracy of CNVs of NTRK3 which predicted platinum-sensitive or platinum-resistant recurrence.We detected CNVs of NTRK3 between 2 groups by array CGH, and amplification of NTRK3 was confirmed by FISH in the platinum-sensitive recurrence group with enlarged samples. The test concordance of 2 methods was 78.6%. Among 41 cases with satisfied FISH results, the median time to recurrence (TTR) of patients with amplified and nonamplified NTRK3 were respectively 18 and 5 months (P <.01). The cut-off value of TTR to differentiate platinum-sensitive or platinum-resistant recurrence was 6 months in accordance with clinical practice. According to the above standard, 15 cases with NTRK3 amplification were platinum-sensitive and 12 cases without NTRK3 amplification were platinum-resistant recurrences which demonstrated that the accuracy of NTRK3 amplification/nonamplification to predict recurrent types was 65.9% (27/41).CNVs of NTRK3 were associated with platinum-sensitive and platinum-resistant recurrences. Amplification of NTRK3 perfectly predicted platinum-sensitive relapse of ovarian cancer.
PMID
Related Publications

Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds.

Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.

Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial.

Ovarian cancer patients with localized relapse: clinical outcome and prognostic factors.

Poor outcome of elderly patients with platinum-sensitive recurrent ovarian cancer: results from the SOCRATES retrospective study.

Authors

Mayor MeshTerms

DNA Copy Number Variations

Keywords
Journal Title medicine
Publication Year Start




PMID- 28746220
OWN - NLM
STAT- MEDLINE
DA  - 20170726
DCOM- 20170807
LR  - 20170807
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Linking)
VI  - 96
IP  - 30
DP  - 2017 Jul
TI  - Copy number variations of neurotrophic tyrosine receptor kinase 3 (NTRK3) may
      predict prognosis of ovarian cancer.
PG  - e7621
LID - 10.1097/MD.0000000000007621 [doi]
AB  - Platinum resistance is a critical barrier for clinicians to improve the survival 
      of ovarian cancer. Our study evaluated the correlation between copy number
      variations (CNVs) of neurotrophic tyrosine receptor kinase 3 (NTRK3) and the
      prognosis of ovarian cancer, which might predict platinum resistance in ovarian
      cancer patients.Array comparative genomic hybridization (CGH) was used to test
      gene backgrounds between platinum-sensitive and platinum-resistant relapsed
      populations and CNVs of NTRK3 were indicated by cluster analysis. Fluorescence in
      situ hybridization (FISH) was adopted in 41 cases for further verification, which
      confirmed the results of array CGH. Spearman's rank correlation analysis and chi 
      test were used to evaluate the accuracy of CNVs of NTRK3 which predicted
      platinum-sensitive or platinum-resistant recurrence.We detected CNVs of NTRK3
      between 2 groups by array CGH, and amplification of NTRK3 was confirmed by FISH
      in the platinum-sensitive recurrence group with enlarged samples. The test
      concordance of 2 methods was 78.6%. Among 41 cases with satisfied FISH results,
      the median time to recurrence (TTR) of patients with amplified and nonamplified
      NTRK3 were respectively 18 and 5 months (P &lt;.01). The cut-off value of TTR to
      differentiate platinum-sensitive or platinum-resistant recurrence was 6 months in
      accordance with clinical practice. According to the above standard, 15 cases with
      NTRK3 amplification were platinum-sensitive and 12 cases without NTRK3
      amplification were platinum-resistant recurrences which demonstrated that the
      accuracy of NTRK3 amplification/nonamplification to predict recurrent types was
      65.9% (27/41).CNVs of NTRK3 were associated with platinum-sensitive and
      platinum-resistant recurrences. Amplification of NTRK3 perfectly predicted
      platinum-sensitive relapse of ovarian cancer.
FAU - Ge, Li
AU  - Ge L
AD  - aDepartment of Gynecologic Oncology bState Key Laboratory of Molecular Oncology, 
      National Cancer Center /Cancer Hospital, Chinese Academy of Medical Sciences and 
      Peking Union Medical College, Beijing, China.
FAU - Li, Ning
AU  - Li N
FAU - Liu, Mei
AU  - Liu M
FAU - Xu, Ning-Zhi
AU  - Xu NZ
FAU - Wang, Ming-Rong
AU  - Wang MR
FAU - Wu, Ling-Ying
AU  - Wu LY
LA  - eng
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Platinum Compounds)
RN  - EC 2.7.10.1 (Receptor, trkC)
SB  - AIM
SB  - IM
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma/*genetics/pathology/therapy
MH  - Cluster Analysis
MH  - Comparative Genomic Hybridization
MH  - *DNA Copy Number Variations
MH  - Drug Resistance, Neoplasm/drug effects/genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Neoplasm Recurrence, Local
MH  - Ovarian Neoplasms/*genetics/pathology/therapy
MH  - Platinum Compounds/therapeutic use
MH  - Prognosis
MH  - Receptor, trkC/*genetics
MH  - Retrospective Studies
EDAT- 2017/07/27 06:00
MHDA- 2017/08/08 06:00
CRDT- 2017/07/27 06:00
AID - 10.1097/MD.0000000000007621 [doi]
AID - 00005792-201707280-00051 [pii]
PST - ppublish
SO  - Medicine (Baltimore). 2017 Jul;96(30):e7621. doi: 10.1097/MD.0000000000007621.